Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab for Immune Checkpoint Inhibitor-related Diarrhea and/or Colitis
NCT06807593Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ustekinumab in Immune checkpoint inhibitor-induced diarrhea and colitis (IMDC), immune-related colitis (IRC), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2026; status: recruiting.
02
Drugs
ustekinumab
03
Conditions
Immune checkpoint inhibitor-induced diarrhea and colitis (IMDC)immune-related colitis (IRC)
Beyond the preview
Go deeper on NCT06807593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06807593.